Objective: This study assessed the rate of major adverse renal or cardiac events (MARCE) when iohexol is used during interventional cardiovascular procedures compared to other low osmolar contrast media (LOCMs).
Although LOCMs have a good safety profile, the possibility of adverse reactions such as acute kidney injury (AKI) should always be considered. 2, 3 The development of contrast-induced AKI (CI-AKI) has been widely documented in the literature and the risk factors of CI-AKI are generally known to include the presence of diabetes and the patient's estimated glomerular filtration rate. 4 CI-AKI is defined as acute renal insufficiency occurring in a patient with normal renal function preceding CM administration or when a patient with chronic renal insufficiency experiences a significant worsening of renal function after CM administration. In some patients, CI-AKI has been associated with progression to advanced stages of chronic kidney disease and an increased risk for major adverse cardiac events (MACE). 5, 6 For example, contemporary insights from the NCDR Cath-PCI registry suggest worsened incidence of bleeding, MI, and death attributed to the development of AKI after PCI. 7 There are a considerable number of reports evaluating the safety of contrast media, though the study methods and findings are variable. [8] [9] [10] [11] [12] [13] There are several meta-analyses of randomized controlled trials (RCT), comparing CI-AKI rates between LOCMs and isoosmolar CM (IOCMs). Preliminary comparisons between patient and hospital characteristics for the hospitals that submit data to Premier and those of the probability sample of hospitals and patients selected for the National Hospital Discharge Survey (NHDS) 17 suggest that the patient populations are similar with regard to patient age, gender, length of stay, mortality, primary discharge diagnosis, and primary procedure groups.
It should be noted that the number of participating hospitals within the database may change over time during the study period.
All data used to perform this analysis were de-identified and accessed in compliance with the Health Insurance Portability and Accountability Act. As a retrospective analysis of a deidentified database, the research was exempt from IRB review under 45 CFR 46.101(b) (4).
| Inclusion criteria and cohort definitions
Inpatient visits with a primary interventional cardiovascular procedure (Supporting Information Appendix A for coding) were included for analysis. Patient encounters were required to have a record of a single, known LOCM (iohexol, ioversol, ioxilan, ioxaglate, or iopamidol).
Visits with an unknown type of contrast (not enough detail in the billing description), IOCM, multiple types of contrast, or no contrast at all were excluded. The attrition diagram (Figure 1) shows the implementation of the inclusion criteria down to the final sample.
| Outcomes
The primary outcome of interest for this study was the composite end point MARCE. MARCE was defined as having occurred in any inpa- 
| Univariate comparisons

| Multivariable models
The decision to utilize a particular product or drug during a hospital visit may depend on formal hospital guidelines, patient comorbidities, physician practice patterns or preferences, negotiated reimbursement schedules with insurance companies, and other local (geographic and/or hospital) characteristics. These elements are mostly unobservable for the purpose of statistical inference. In this study, multivariable regression analysis was conducted using the hospital fixed-effects specification to assess the relationship between the type of CM used and MARCE events. The hospital fixed-effect specification methodology was chosen to control for timeinvariant within-hospital variation that are otherwise unobservable in the choice of CM, such as hospital protocols which specify which contrast media is used. The fixed-effects model allowed for control of hospitals' unobserved internal rules on product assignment (hospital indicator). In addition, all models controlled for the following covariates: patient demographics (year, age, gender, race marital status, admission type, and insurance group), comorbidities (categories of the Elixhauser Comorbidity Index) and reason for hospitalization (primary procedure and primary diagnosis).
| Sensitivity analysis
The other LOCM cohort was further subdivided by each of the individ- 
| Univariate
Univariate analysis of the cohorts found no significant difference in the mean age of the cohorts, but statistically significant differences in other demographic characteristics existed (Table 1) ; however, many of these differences were quite small and potentially due to the very large sample sizes. Iohexol had higher rates of use in Caucasian and male patients.
There were also slight differences in insurance provider and admission type. Patient comorbidity scores were slightly higher in the iohexol cohort, whereby iohexol cohort had significantly higher rates of valvular disease (17% vs. 14%, P ≤ 0.0001), cardiac arrhythmia (41% vs. 38%, P ≤ 0.0001), and depression (10% vs. 9%, P ≤ 0.0001) ( The iohexol cohort had a significantly different distribution of hospital region (P ≤ 0.0001), compared with the other LOCMs cohort, with more visits coming from the northeast and west (Table 3) . Also, the iohexol cohort had more visits from urban hospitals (P ≤ 0.0001), teaching hospitals (P ≤ 0.0001), and larger bed size hospitals (P ≤ 0.0001). The univariate MARCE rates were slightly higher in the other LOCMs cohort (7.9% vs. 7.7%, P = 0.0077) before multivariable modeling (Table 4) .
| Multivariable
Using the hospital fixed-effects specification, while controlling for patient demographics, comorbid conditions, and primary diagnosis/procedure, differences in MARCE rates between iohexol and other LOCMs
were not statistically significant (Figure 2) . When analyzing the individual components of the MARCE composite endpoint, iohexol had a slightly higher estimated incidence of stent occlusion/thrombosis 
| Sensitivity analysis
As a sensitivity analysis, the MARCE and renal composite endpoints were analyzed separately comparing iohexol vs. ioversol and iohexol vs. iopamidol without finding significant differences (Figure 3 ). There was insufficient sample size to directly compare iohexol with ioxaglate or ioxilan.
| DISCUSSION
Despite prior concerns regarding iohexol, we found no evidence of increased MARCE among those who received iohexol as compared to meta-analysis showed that both iohexol and ioxaglate had higher CI-AKI rates than an IOCM. 13 It is important to note that there is no pub- 
| Strengths and limitations
The strengths of this study include the use of a comprehensive data source and use of the hospital fixed-effect specification methodology that controlled for time-invariant within hospital variation that is otherwise unobservable, such as physician preferences and internal protocols. This study has limitations, which are inherent to retrospective database analyses. These include the unit of inference, which was the visit and not the patient, and the lack of longitudinal tracking of a patient. Thus, it was not possible to determine if events occurred after the patient was discharged. Laboratory values
were not available, thus we could not define CI-AKI by serum creatinine levels, and rather the outcome was defined by the ICD-9 code for CI-AKI which may underestimate the occurrence of this event.
The data source for this study was the Premier Healthcare Database which represents 20% of all inpatient discharges in the US; however, given its reliance on ICD-9 codes, even with validation efforts, Multivariable model results-iohexol vs. ioversol and iopamidol. The figure shows the parameter estimates with confidence intervals from of a sensitivity analysis in which the MARCE and renal composite endpoints were analyzed separately comparing iohexol to ioversol and iohexol to iopamidol. The sensitivity analysis used multivariable modeling with hospital fixed-effects specification, controlled for patient demographics, comorbid conditions, and primary diagnosis/procedure. No differences were found in the rate of MARCE or renal adverse events between iohexol and ioversol nor between iohexol and iopamidol. MARCE: major adverse renal or cardiac events
